

Developing and delivering new TB vaccines will require unprecedented commitment, engagement, and partnership from a diverse group of public and private sector partners across all aspects of TB vaccine development and delivery.

Partnerships for success

To rapidly develop and deliver new TB vaccines, we need to collectively increase, consolidate, and harmonize our expertise and efforts on **four complementary objectives**.

- Diversify the pipeline
- Accelerate clinical trials
- Maximize public health impact
- Roll-out vaccines in a rapid, accessible, and equitable way

Only together can we bring about new TB vaccines and help end TB once and for all.

Global endeavor

The significant advances in TB vaccine development is due to the ingenuity and perseverance of researchers, product developers, political leaders, funders, policymakers, advocates, affected people and communities, and many others around the world.

Key partner groups

Research Partners

- Universities
- Academic research centers
- Clinical trial sites

Product Developers

- Private sector
- Manufacturers
- Product Development Partnerships (PDPs)

Health Care Providers

- Public, private, & community-based healthcare workers

Global Health & TB Organizations


- Advocacy organizations
- Multilateral agencies

Procurement agencies

- Global, regional, & national agencies

Historic moment

- Multiple promising TB vaccine candidates are in late-stage efficacy testing
- Efforts are underway to ensure new TB vaccines will be affordably and equitably accessible to all who need them
- Cutting-edge technologies are bringing forth next-generation TB vaccines
- Novel insights into the human immune response to *Mycobacterium tuberculosis* infection continue to inform and refine our research



Public Health Agencies & Programs

- International, regional, & national public health agencies
- National TB Programs
- National Immunization Programs
- National Immunization Technical Advisory Groups

Governments

- Ministries of Health, Research, Finance, Biotechnology, & others
- Members of Parliament
- Regulatory agencies

Funders

- Public and private

Civil society

- Affected communities
- International & country-level NGOs

Networks

- Research networks
- Advocacy networks
- Community advisory boards

Communications & Capacity Building

- Media
- Influencers/social media